Psychedelic-Assisted Therapy

Psilocybin, MDMA and ketamine sit at the contested frontier of addiction therapy. The session covers psilocybin in alcohol and tobacco use disorders, MDMA-assisted therapy for PTSD with comorbid SUD (post-Lykos CRL trial-design lessons), the FDA pathway after the 2024 advisory committee, therapist training and equity in access, Oregon and Colorado state regulated psilocybin programmes, the Compass Pathways and Cybin pipelines, and the distinction between therapeutic and recreational ketamine use. Discussion addresses safety in adolescents and older adults, real-world implementation in community clinics, payor coverage, and the ethical considerations of psychedelic-assisted therapy in marginalised populations.